The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

References

• Stauffer M, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014;9(1):e84943.
   PubMed Web of Science ®Google Scholar
• Kdoqi. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471–530.
   PubMed Web of Science ®Google Scholar
• Hung SC, Lin YP, Tarng DC. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc 2014;113(1):3–10.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146–55.
   PubMed Web of Science ®Google Scholar
• Smrzova J, Balla J, Barany P. Inflammation and resistance to erythropoiesis-stimulating agents–what do we know and what needs to be clarified? Nephrol Dial Transplant2005;20(Suppl. 8):viii2–7.
   PubMedGoogle Scholar
• Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18(7):1272–80.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant 2003;18(Suppl. 8):viii17–22.
   PubMedGoogle Scholar
• Tutal E, Sezer S, Bilgic A, Aldemir D, Turkoglu S, Demirel O, et al. Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values ‘in normal range’. Transplant Proc 2007;39(10):3035–40.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65(1):49–57.
   PubMed Web of Science ®Google Scholar
• Iain CM,, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002;17(Suppl. 11):39–43.
   Google Scholar
• Cooper A, Mikhail A, Lethbridge M, Kemeny D, Macdougall I. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15(7):1877–82.
   PubMed Web of Science ®Google Scholar
• Mohammadpour A, Nazemian F, Khaiat M, Tafaghodi M, Salari P, Charkazi S, et al. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi J Kidney Dis Transpl 2014;25(1):73–8.
   PubMedGoogle Scholar
• Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 2008;9:8.
   PubMed Web of Science ®Google Scholar
• Briskey D, Wilson G, Fassett R, Coombes J. Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2014;90:161–6.
   PubMed Web of Science ®Google Scholar
• Levine R, Garland D, Oliver C, Amici A, Climent I, Lenz A, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464–78.
   PubMed Web of Science ®Google Scholar
• Madesh M, Balasubramanian K. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys 1998;35(3):184–8.
   PubMed Web of Science ®Google Scholar
• Wheeler C, Salzman J, Elsayed N, Omaye S, Korte DJ. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal Biochem 1990;184(2):193–9.
   PubMed Web of Science ®Google Scholar
• Roger S, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (Carlton) 2004;9(4):223–8.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, BEc PC, et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65(1):49–57.
   PubMed Web of Science ®Google Scholar
• Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65(3):1009–16.
   PubMed Web of Science ®Google Scholar
• Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008;19(3):593–9.
   PubMed Web of Science ®Google Scholar
• Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59(5):1960–6.
   PubMed Web of Science ®Google Scholar
• Wiswedel I, Peter D, Gardemann A, Carluccio F, Hampl H, Siems W. Serum concentrations of F2-isoprostanes and 4-hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemia. Biomark Insights 2008;3:419–28.
   PubMedGoogle Scholar
• Tbahriti HF, Kaddous A, Bouchenak M, Mekki K. Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int 2013;2013:358985.
   PubMedGoogle Scholar
• Aveles PR, Criminacio CR, Goncalves S, Bignelli AT, Claro LM, Siqueira SS, et al. Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract 2010;116(4):c294–9.
   PubMedGoogle Scholar
• Zachara BA, Gromadzińska J, Wąsowicz W, Zbróg Z. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006;53(4):663–77.
   PubMed Web of Science ®Google Scholar
• Iasioli S, Schiavon R, Petrosino L, Cavallini L, De Fanti E, Zambello A, et al. Do different dialytic techniques have different atherosclerotic and antioxidant activities? ASAIO J 2001;47(5):516–21.
   PubMed Web of Science ®Google Scholar
• Gallucci M, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, et al. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 1999;52(4):239–45.
   PubMed Web of Science ®Google Scholar
• Suliman HB, Ali M, Piantadosi CA. Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia. Blood 2004;104(1):43–50.
   PubMed Web of Science ®Google Scholar
• Rusu A, Rusu F, Zalutchi D, Muresan A, Gherman Caprioara M, Kacso I. The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase. Int Urol Nephrol 2013;45(2):495–501.
   PubMed Web of Science ®Google Scholar
• Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009;54(6):1089–97.
   PubMed Web of Science ®Google Scholar
• Kamgar M, Zaldivar F, Vaziri N, Pahl M. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 2009;101(4):336–44.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007;17(5):296–304.
   PubMed Web of Science ®Google Scholar